Scienmag

SEPTEMBER 18, 2020

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

Protein 53

Protein Antibody In-Vitro Scientist 53

Pharmaceutical Technology

FEBRUARY 22, 2023

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. To an extent, the challenge here lies in the nature of antibodies, says Contreras. Both drugs come with a high price tag.

Antibody 262

Antibody Drugs Protein Sales 262

Scienmag

APRIL 22, 2021

SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity Researchers have identified another potential target for neutralizing antibodies on the SARS-CoV-2 Spike protein that is masked by metabolites in the blood.

Antibody 46

Antibody Protein Scientist Research 46

Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

Scienmag

NOVEMBER 4, 2020

Credit: Rayne Zaayman-Gallant/EMBL The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2. To enable the virus to hook onto the cell surface, the spike protein binds ACE2 using three finger-like protrusions, called the receptor binding domains (RBDs).

Scientist 65

Scientist Antibody Protein Medicine 65

Pharmaceutical Technology

JULY 6, 2022

Scientists at the National Institutes of Health (NIH) unit National Institute of Neurological Disorders and Stroke (NINDS) have found that Covid-19-induced immune response could damage the blood vessels of the brain and may lead to short and long-term neurological symptoms. .

Immune Response 162

Immune Response Antibody Gene DNA 162

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

Scienmag

MAY 6, 2021

Inserting active-agent proteins into cancer cells using antibodies The ability of antibodies to recognize specific cancer cells is used in oncology to specifically target those cells with small active agents.

Protein 75

Protein Antibody Scientist Drugs 75

Pharmaceutical Technology

NOVEMBER 29, 2022

For this approach, the team leveraged an oncolytic herpes simplex virus for releasing chemokines, which are signalling proteins that aid in attracting immune cells to tumours. Using chemokines, the scientists made the GBM tumours “hot”, making the chemokines aid in the immune cell migration to the tumour microenvironment.

Development 130

Development Research Antibody Engineer 130

pharmaphorum

SEPTEMBER 1, 2020

GlaxoSmithKline and US-based Vir Biotechnology are to trial a new therapy for COVID-19 based on an antibody designed to neutralise the SARS-CoV-2 coronavirus. The move brings GSK and Vir into competition with Sanofi and Regeneron, who are developing a cocktail based around two antibodies that could be effective against the virus.

Antibody 59

Antibody Protein Trials Vaccination 59

Pharmaceutical Technology

APRIL 28, 2023

Its scope includes Syngene providing integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. until 2026. Syngene’s collaboration with Zoetis started in 2011.

Manufacturing 130

Manufacturing Antibody Clinical Supply Protein 130

pharmaphorum

AUGUST 12, 2021

A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH) has provided protection for people exposed to malaria parasites for up to nine months. The post More malaria hope as antibody protects against infection appeared first on.

Antibody 64

Antibody Vaccination Vaccine Allergies 64

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. In addition, the scientists later found that the HAV needs TENT4A/B for its replication.

Protein 130

Protein RNA Genomics Genome 130

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 75

Vaccination Vaccine Immune Response Containment 75

The Pharma Data

FEBRUARY 12, 2022

The COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the base of its spike protein that is found also on closely related coronaviruses, according to a new study from Scripps Research. In the new work, they mapped at atomic scale the site, or “epitope,” to which the antibody binds on the SARS-Cov-2 spike protein.

Scientist 52

Scientist Antibody Protein Vaccination 52

Pharmaceutical Technology

MAY 19, 2023

The contentious battle is centred around two monoclonal antibodies that inhibit the protein PCSK9, which in turn lowers low-density lipoprotein (LDL) cholesterol levels. According to the company, such an approach is dangerous since companies could claim a whole genus of antibodies without discovering them.

Drugs 147

Drugs Antibody Protein Scientist 147

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. VOC 202012/01 has an unusually high number of genetic changes however, with 10 mutations affecting the spike protein. lineage or VOC 202012/01.

Vaccination 98

Vaccination Vaccine Antibody Protein 98

The Pharma Data

OCTOBER 27, 2021

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat COVID-19. The neutralizing activity of the sera developed by the scientists has been proved to be high against the P.1 1 (Gamma) and P.2

Antibody 52

Antibody Protein Scientist Clinical Trials 52

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants. bioRxiv [Preprint]. 2021 Apr 8:2021.04.08.438884. Source link: [link].

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

SEPTEMBER 30, 2021

Scientists from the German Cancer research facility (DKFZ) and therefore the Medical Faculty Mannheim, Heidelberg University, have now identified a replacement protein produced by blood vessels that permits tumor cells to metastatically colonize organs.

Protein 52

Protein Scientist Antibody Research 52

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community.

Scientist 52

Scientist Immune Response Antibody Development 52

Scienmag

OCTOBER 23, 2020

The technique should help in the design of vaccines against HIV, SARS-CoV-2 and other viruses that cloak their outer proteins with sugars to evade antibodies.

Protein 61

Protein Antibody Scientist Vaccination 61

The Pharma Data

DECEMBER 7, 2020

7, 2020 — Scientists say they may be getting closer to creating a universal flu vaccine. The vaccine produces antibodies that target the part of the surface protein of the influenza virus known to neutralize different influenza strains, the researchers said. MONDAY, Dec.

Vaccination 52

Vaccination Vaccine Scientist Immune Response 52

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. Patients have better quality of life thanks to many Grifols plasma-derived medicines that replace missing or deficient plasma proteins.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

The Pharma Data

NOVEMBER 2, 2020

2, 2020 — An experimental antibody drug that targets one of the body’s key metabolism regulators may help obese people lose weight — at least briefly. It would take much more research to prove the antibody is safe and effective, Ryan said. Scientists have tried giving modified versions of FGF21 to benefit metabolism.

Antibody 52

Antibody Drugs Hormones Insulin 52

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . The partners want to focus on riskier, more complex structures of proteins to try to decipher them.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

XTalks

JANUARY 11, 2023

The new subvariant has also been dubbed “Kraken” by some scientists. on the horizon as scientists say the virus appears to be rapidly evolving , mutating faster than most viruses. Thanks to large-scale sequencing efforts, scientists in the US have been keeping a close eye on XBB. and its descendants.

Scientist 98

Scientist Vaccination Vaccine Genetics 98

pharmaphorum

MAY 19, 2022

Moderna’s vaccines deliver HIV-specific antigens discovered by researchers at IAVI and Scripps Research that have already been tested in a proof-of-concept study carried out last year using an adjuvant protein vaccine approach. HVAD #HVAD2022 pic.twitter.com/KLrVRXtEAv. — Moderna (@moderna_tx) May 18, 2022.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

XTalks

APRIL 22, 2022

Generally, antibody-based therapeutics are one of the main types of drugs that are assessed using receptor occupancy assays as they bind to specific cell surface receptors through which they impact downstream intracellular signalling pathways. The antibodies are conjugated to fluorochromes for them to be detected.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

Find Me Cure

APRIL 23, 2020

The far more boring truth is that scientists are not magicians or prophets and estimations cannot always be precise. Firstly, even though scientists are busy developing a vaccine, one is not expected earlier than 2021. Scientists have no way of predicting how a certain organism is going to respond to the virus at this point.

Immune Response 117

Immune Response Antibody Scientist Development 117

pharmaphorum

DECEMBER 21, 2020

As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein. In this case that is the “spike” protein seen on the surface of the coronavirus that it uses to invade host cells.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

The Pharma Data

JANUARY 12, 2021

million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

Worldwide Clinical Trials

MAY 30, 2024

Tofersen (Intrathecal injection) This is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. Other researchers are investigating approaches that use AAV-mediated trophic support and antibody-based therapies, such as vaccines and small molecule drugs, to modify various protein expressions.

Gene 204

Gene Clinical Trials Clinical Trials Gene Therapy 204

The Pharma Data

MARCH 22, 2021

Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days. The combination of casirivimab and imdevimab is the only monoclonal antibody treatment to retain potency against key emerging variants, based on the recently updated EUA guidance from the U.S.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 29, 2020

First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. futility analysis).

Antibody 52

Antibody Trials Production Clinical Trials 52

Pharmaceutical Technology

AUGUST 24, 2022

More than three decades ago, scientists at the National Cancer Institute began exploring ways to fight cancer using the patient’s immune system. The global immunotherapy market, which includes CAR T-cell therapy, adoptive cell therapies, checkpoint inhibitors, monoclonal antibodies, and other immunotherapies, is expected to grow by 10.1%

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. About REGN-COV2 REGN-COV2 was designed specifically by Regeneron scientists to block infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron will distribute REGN-COV2 in the U.S.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52